Search Results - "Nuciforo, P"

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors by Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A.J., Nuciforo, P., Tabernero, J.

“…The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell proliferation, angiogenesis, migration and survival. Accumulating…”
Get full text

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer by Serna, G., Ruiz-Pace, F., Hernando, J., Alonso, L., Fasani, R., Landolfi, S., Comas, R., Jimenez, J., Elez, E., Bullman, S., Tabernero, J., Capdevila, J., Dienstmann, R., Nuciforo, P.

“…Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer. Nevertheless, only limited data…”
Get full text

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer by Oliveira, M., Saura, C., Nuciforo, P., Calvo, I., Andersen, J., Passos-Coelho, J.L., Gil Gil, M., Bermejo, B., Patt, D.A., Ciruelos, E., de la Peña, L., Xu, N., Wongchenko, M., Shi, Z., Singel, S.M., Isakoff, S.J.

“…This hypothesis-generating trial evaluated neoadjuvant ipatasertib–paclitaxel for early triple-negative breast cancer (TNBC). In this randomized phase II…”
Get full text

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer by Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J.M., Paéz, D., Falcó, E., Lopez Lopez, C., Aranda, E., Jones, F., Sikri, V., Nuciforo, P., Fasani, R., Tabernero, J., Montagut, C., Azuara, D., Dienstmann, R., Salazar, R., Vivancos, A.

“…Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue…”
Get full text

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle by De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H.H., Ng, C.K.Y., Nuciforo, P., Bidard, F.-C., Aura, C., Saura, C., Peg, V., Piscuoglio, S., Oliveira, M., Smolders, Y., Patel, P., Norton, L., Tabernero, J., Berger, M.F., Seoane, J., Reis-Filho, J.S.

“…Plasma-derived cell-free tumor DNA (ctDNA) constitutes a potential surrogate for tumor DNA obtained from tissue biopsies. We posit that massively parallel…”
Get full text

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer by Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y.H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O.M., Lai, Z., Polanska, U.M., Jones, G.N., Kristel, P., de Bustos, L., Guzman, M., Rodríguez, O., Grueso, J., Montalban, G., Caratú, G., Mancuso, F., Fasani, R., Jiménez, J., Howat, W.J., Dougherty, B., Vivancos, A., Nuciforo, P., Serres-Créixams, X., Rubio, I.T., Oaknin, A., Cadogan, E., Barrett, J.C., Caldas, C., Baselga, J., Saura, C., Cortés, J., Arribas, J., Jonkers, J., Díez, O., O’Connor, M.J., Balmaña, J., Serra, V.

“…BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to…”
Get full text

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin by Capdevila, J., Hernando, J., Teule, A., Lopez, C., Garcia-Carbonero, R., Benavent, M., Custodio, A., Garcia-Alvarez, A., Cubillo, A., Alonso, V., Carmona-Bayonas, A., Alonso-Gordoa, T., Crespo, G., Jimenez-Fonseca, P., Blanco, M., Viudez, A., La Casta, A., Sevilla, I., Segura, A., Llanos, M., Landolfi, S., Nuciforo, P., Manzano, J. L.

“…Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity…”
Get full text

Early evolutionary divergence between papillary and anaplastic thyroid cancers by Capdevila, J., Mayor, R., Mancuso, F.M., Iglesias, C., Caratù, G., Matos, I., Zafón, C., Hernando, J., Petit, A., Nuciforo, P., Cameselle-Teijeiro, J.M., Álvarez, C., Recio, J.A., Tabernero, J., Matias-Guiu, X., Vivancos, A., Seoane, J.

“…Papillary thyroid cancer (PTC) is the most common thyroid carcinoma and exhibits an almost uniformly good prognosis, while anaplastic thyroid cancer (ATC) is…”
Get full text

The search for simplicity: is this compatible with precision medicine? by Nuciforo, P.G.

Get full text

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade by Nuciforo, P., Pascual, T., Cortés, J., Llombart-Cussac, A., Fasani, R., Paré, L., Oliveira, M., Galvan, P., Martínez, N., Bermejo, B., Vidal, M., Pernas, S., López, R., Muñoz, M., Garau, I., Manso, L., Alarcón, J., Martínez, E., Rodrik-Outmezguine, V., Brase, J.C., Villagrasa, P., Prat, A., Holgado, E.

“…The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathologic complete response (pCR) and improved outcomes in…”
Get full text

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial by Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D.D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D.L., Baselga, J., Pusztai, L.

“…We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or…”
Get full text

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells by Cebrià-Costa, J. P., Pascual-Reguant, L., Gonzalez-Perez, A., Serra-Bardenys, G., Querol, J., Cosín, M., Verde, G., Cigliano, R. A., Sanseverino, W., Segura-Bayona, S., Iturbide, A., Andreu, D., Nuciforo, P., Bernado-Morales, C., Rodilla, V., Arribas, J., Yelamos, J., de Herreros, A. Garcia, Stracker, T. H., Peiró, S.

“…Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2…”
Get full text

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer by Veeraraghavan, J., De Angelis, C., Mao, R., Wang, T., Herrera, S., Pavlick, A.C., Contreras, A., Nuciforo, P., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Chang, J.C., Wolff, A.C., Krop, I.E., Fuqua, S.A.W., Prat, A., Hilsenbeck, S.G., Weigelt, B., Reis-Filho, J.S., Gutierrez, C., Osborne, C.K., Rimawi, M.F., Schiff, R.

“…HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet,…”
Get full text

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) by Martinez-Marti, A, Felip, E, Matito, J, Mereu, E, Navarro, A, Cedrés, S, Pardo, N, Martinez de Castro, A, Remon, J, Miquel, J M, Guillaumet-Adkins, A, Nadal, E, Rodriguez-Esteban, G, Arqués, O, Fasani, R, Nuciforo, P, Heyn, H, Villanueva, A, Palmer, H G, Vivancos, A

“…Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of…”
Get full text

Early evolutionary divergence between papillary and anaplastic thyroid cancers by Capdevila, J., Mayor, R., Mancuso, F.M., Iglesias, C., Caratú, G., Matos, I., Zafón, C., Hernando, J., Petit, A., Nuciforo, P., Cameselle-Teijeiro, J.M., Álvarez, C.V., Recio, J.A., Tabernero, J., Matias-Guiu, X., Vivancos, A., Seoane, J.

Get full text

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer by Griguolo, G., Serna, G., Pascual, T., Fasani, R., Guardia, X., Chic, N., Paré, L., Pernas, S., Muñoz, M., Oliveira, M., Vidal, M., Llombart-Cussac, A., Cortés, J., Galván, P., Bermejo, B., Martínez, N., López, R., Morales, S., Garau, I., Manso, L., Alarcón, J., Martínez, E., Villagrasa, P., Prat, A., Nuciforo, P.

“…Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within…”
Get full text

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status by Nuciforo, P.G., Aura, C., Holmes, E., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Peña, L., Ellis, C., Eidtmann, H., Piccart-Gebhart, M.J., Scaltriti, M., Baselga, J.

“…Assessment of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) might be an important tool in identifying human epidermal growth factor receptor…”
Get full text

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial by Shi, W, Jiang, T, Nuciforo, P, Hatzis, C, Holmes, E, Harbeck, N, Sotiriou, C, Peña, L, Loi, S, Rosa, D D, Chia, S, Wardley, A, Ueno, T, Rossari, J, Eidtmann, H, Armour, A, Piccart-Gebhart, M, Rimm, D L, Baselga, J, Pusztai, L

Get full text

Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor by Confalonieri, S, Quarto, M, Goisis, G, Nuciforo, P, Donzelli, M, Jodice, G, Pelosi, G, Viale, G, Pece, S, Di Fiore, P P

“…Protein ubiquitination is critical for many cellular processes, through its ability to regulate protein degradation and various signaling mechanisms. In the…”
Get full text

First-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors by Calvo, E, Aftimos, P G, Azaro, A, de Miguel, M J, Jungels, C, Zeron-Medina Cuairan, J, Nuciforo, P G, Ehmer, P, Martin, A, Bender, H K, Dembowsky, K

Get full text